A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)

Recruiting now · Phase 1 · Has a placebo group

Conditions studied: Atopic Dermatitis

In brief

This is a Phase 1, randomized, blinded, placebo controlled, single ascending dose (SAD) study of BBT001 in healthy volunteers (HVs) and adult patients with moderate to severe Atopic Dermatitis (AD).

Key facts

Study ID

NCT07239947

Run by

Bambusa Therapeutics

People needed

99

Starts

2025-08-09

Expected to finish

2028-06-30

Last updated by the study team

2026-07-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

Where it is running

• The Second Hospital of Anhui Medical Univesity — Hefei, Anhui, China (enrolling)
• The Second Affiliated Hospital of Wannan Medical College — Wuhu, Anhui, China
• Peking University People's Hospital — Beijing, Beijing Municipality, China
• Dermatology Hospital of Southern Medical University — Guangzhou, Guangdong, China
• The Second Xiangya Hospital of Central South University — Changsha, Hunan, China
• Wuxi Second People's Hospital — Wuxi, Jiangsu, China
• Jiangsu University Affiliated Hospital — Zhenjiang, Jiangsu, China
• Jiangxi Provincial Dermatology Hospital — Nanchang, Jiangxi, China
• Shandong Provincial Hospital for Skin Diseases — Jinan, Shandong, China
• Shanghai Dermatology Hospital — Shanghai, Shanghai Municipality, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.